Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Zhejiang Medicine Collaborates with Ambrx and WuXi on Breast Cancer Drug

publication date: Jun 17, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Zhejiang Medicine Co. formed a collaboration with Ambrx of San Diego to develop an Ambrx molecule that targets Her2-positive breast cancer. Ambrx genetically engineers proteins that contain new amino acids with different properties than those of the 20 natural-occurring amino acids. The company’s technology is centered on antibody-drug conjugates, which combine a targeting agent and a cytotoxic. In return for China rights, Zhejiang will underwrite the costs of development, which will be carried out by WuXi PharmaTech. More details....

Stock Symbols: (SHA: 600216) (NYSE: WX)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at these events:
 
 
 
Hope to see you there!
 
ChinaBio® Events
ChinaBio Leadership Retreat 2014
Suzhou, China
October 23-24, 2014
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors